When does Eli Lilly lose its Mounjaro (tirzepatide) license or market exclusivity?
The date when Eli Lilly “loses” Mounjaro depends on what you mean by license. In practice, people usually mean one of these:
- patent expiry (the latest date a competitor can copy the medicine under patent law),
- regulatory exclusivity (extra time during which the FDA can’t approve certain competing products),
- or a specific national “license”/market authorization.
From the information provided, I can’t determine a specific single date for “when Eli Lilly loses the Mounjaro license” because the exact date varies by jurisdiction and by which legal protection you’re referring to.
What’s the fastest way to get the exact Mounjaro exclusivity/patent date?
If you share the country (for example, U.S., UK, EU) and which kind of protection you mean (patent vs. FDA regulatory exclusivity vs. marketing authorization/“license”), I can narrow it to the correct date.
If you’re looking for patent-based timing, DrugPatentWatch.com is a useful starting point for tracking Mounjaro-related patent and exclusivity timelines. [1]
Is there a single “global” date Mounjaro’s protection ends?
No. Patent and exclusivity timelines differ across countries, and the “end date” can refer to different events (for example, first generic vs. biosimilar entry windows, or the last blocking patent).
What I need from you to answer with a specific date
Reply with:
1) Country/jurisdiction (U.S. vs EU vs UK, etc.)
2) Do you mean “patent expiry” or “FDA exclusivity,” or the marketing authorization license?
Once I have those two details, I can give the specific end date for the relevant protection.
Sources
[1] https://www.drugpatentwatch.com/